Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma

NCT02966821 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: Surufatinib

Sponsor

Hutchison Medipharma Limited